3/10/2003 Patent Ductus Arteriosus Occlusion Device Oral Presentation #3 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle.

Slides:



Advertisements
Similar presentations
Heat Loss Calculator for a Stainless Steel Complex Pipe System By: Thomas Morris & Jacob Hannon.
Advertisements

Tutorial June 25 Bio 155. Blood Cellular component: 1)RBC 2)WBC 3)Platelet.
Indicated for Arterial and Venous Embolizations in the Peripheral Vasculature April, 2004.
Pinhas (Peter) Dartal 01 June QA role in development of Percutaneous Aortic Valve prosthesis.
TRANSCATHETER PDA CLOSURE USING THE AMPLATZER DUCT OCCLUDER
 A 'heat exchanger' may be defined as an equipment which transfers the energy from a hot fluid to a cold fluid. Here, the process of heating or cooling.
By Justin Martin.  The veins carry oxygen depleted blood back to the heart from the rest of the body.  In the legs, the veins have to fight gravity.
PATENT DUCTUS ARTERIOSUS By: Nicole Stevens. Patent Ductus Arteriosus is a functional connection between the pulmonary artery and the descending aorta.
2 Heartworms and Heart Murmurs Partnership for Environmental Education and Rural Health Texas A&M University An introduction to problems.
An Essential Need of Modern Civilization… P M V Subbarao Professor Mechanical Engineering Department I I T Delhi Viscous Fluid Flows in Ducts.
Concept Generation Mechanical Actuator for Magnetic Resonance Elastography of the Lumbar Spine Overview Background Information Project Scope Metrics Design.
CPAP Remote Alarm System BME 272: Oral Report Two Group 15 Kathleen Grunder Jessica Paulsen Molly Rice.
INTRODUCTION A 35 year old woman with transposition of the great arteries repaired with a Mustard procedure attends your clinic for annual follow-up. Her.
Lockout/tagout Authorized employees
Copyright © 2005, 2002, 1997, 1992 by Mosby, Inc. All rights reserved. Chapter 14 The Circulation of the Blood.
Abstract A patient who had transcatheter closure of a large patent ductus arteriosus in early infancy developed aortic coarctation during follow-up. Initially.
A Novel Dermoscopic Probe for Determining Elasticity Measurements of the Skin Erica Bozeman 1, Markesha Cook 1, Stephanie Cruz 1 Advisor: Michael Miga,
Vanessa Beretta & Dan Fleming. About CHD A congenital heart defect also known as CHD is a defect in the structure of the heart and great vessels. Most.
Heart Stabilization Device Amir Durrani Ben Hoagland Santosh Tumkur Lucas Burton Advisor: Thomas P. Ryan, Ph.D.
Patent Ductus Arteriosus Occlusion Device David Brogan *, Darci Phillips *, Daniel Schultz *, Dr. Thomas Doyle ‡ * Vanderbilt University Biomedical Engineering.
Improving Field-Induced Magnetic Nanoparticle Drug Delivery BME 273 Group 15 Team Leader : Ashwath Jayagopal (BME, EE, MATH) Members : Sanjay Athavale.
Cardiovascular surgery, Congenital heart disease Dr. Robin Man Karmacharya, Lecturer, Department of Surgery, Dhulikhel Hospital.
Transcatheter ASD closure, sans X-rays Peter Ewert MD Robert Beekman MD.
Measuring Neonatal Lung Volume
Pulmonary Flow Resistive Device Taya Furmanski Albert Attia Advisor: Thomas Doyle, M.D. April 9, 2003.
Patent Ductus Arteriosis (PDA)
NANS I3 Technology Gaps in Intrathecal Drug Delivery Systems
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
DR AFTAB YUNUS FRCSEd. CHAIRMAN CARDIAC SURGERY
Gene Therapy Prof. Dr. Marlina, MS, Apt Kuliah I 14 Maret 2011 Mata Kuliah: Bioteknologi Farmasi.
Sutureless Percutaneous Anastamosis Device Steve Chen Jamal Siddiqui.
Project Undertaken by: Fritz Haimberger
Cauterization Catheter – An Advancement in Conductive Biomaterials and Medicine C. Blyth 1, C. Fernandez 1, S. Hittinger 1, C. Jones 1, B. McGee 1 Advisors:
Pulmonary Embolism Extraction Catheter Development Trip Cothren Lauren Nichols Dustin Temple Advised by: Dr. Michael Barnett, VUMC Cardiology.
Patent Ductus and Vascular Occlusion Devices Ornob Roy Elaine Isom Michelle Carlsen Brad Klosterman Advisor: Dr. Thomas Doyle.
Sutureless Percutaneous Anastamosis Device Steve Chen Jamal Siddiqui.
Improving CABG Surgery
Mixing and Injection System for Polyurethane Scaffolds Michael Scherer Dustin Dowell Andrew Solomon February 21 th, 2007.
Patent Ductus and Vascular Occlusion Devices Michelle Carlsen Elaine Isom Brad Klosterman Ornob Roy Advisor: Dr. Thomas Doyle.
Pulmonary Flow Resistive Device Taya Furmanski Albert Attia Advisor: Thomas Doyle, M.D. March 17, 2003.
Pulmonary Flow Resistive Device Taya Furmanski Albert Attia Advisor: Thomas Doyle, M.D. February 12, 2003.
Modelling E4: Human Factors Design IB Technology.
Patent Ductus and Vascular Occlusion Devices Michelle Carlsen Elaine Isom Brad Klosterman Ornob Roy Advisor: Dr. Thomas Doyle.
Emergency Airways Modification of Transtracheal Jet Ventilation and Retrograde Intubation Techniques BME 272 Senior Design Group 20 Project Undertaken.
Chris Burke, MD. What is the Ductus Arteriosus? Ductus Arteriosus  Allows blood from RV to bypass fetal lungs  Between the main PA (or proximal left.
Congenital Heart Disease
Occlusion Device for Patent Ductus Arteriosus Christina Mathieson & Trung Nguyen Advisor: Dr. Tom Doyle BME 273 – Senior Design Project.
2/14/2003 Patent Ductus Arteriosus Occlusion Device Oral Presentation #2 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle.
Patent Ductus Arteriosus Occlusion Device Christina Mathieson Trung Nguyen Advisor: Dr. Tom Doyle BME 273 – Senior Design Project.
Determine method of rapid prototyping or plastic extrusion to create prototype of true-to-scale catheter Determine optimal slot size without affecting.
4/11/2003 Patent Ductus Arteriosus Occlusion Device Oral Presentation #4 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle.
January 26, 2004BME 272/2731 Investigation of Bubble Formation in Tuohy-Borst Adaptors Department of Biomedical Engineering Melanie Bernard, Isaac Clements,
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Further experience with transcatheter closure of.
Issues and Current Situations in the Development of Endovascular Treatment Devices for Pediatric Cardiology in the US – US Industry Dan Gutfinger, MD,
Improving CABG Surgery
Clinical engineering Lecture (8).
Percutaneous Closure of a Coronary Fistula
Chronic heart failure.
Laurence Soriano Haena rose tamayo Pamela galang Sandeep kaur
Patent Ductus Arteriosus Occlusion Device
Measuring Neonatal Lung Volume
Client: Dr. Jonathan Jaffery Advisor- Brenda Ogle
Improving Coronary Artery Bypass Surgery
Robotic Needle End Arm Effector for Integration With CT Scan
Improving CABG Surgery
Patent Ductus Arteriosus Occlusion Device Oral Presentation #1
Sutureless Percutaneous Anastamosis Device
Sutureless Percutaneous Anastamosis Device
Fetal Circulation pp
Endoluminal Closure Device
Presentation transcript:

3/10/2003 Patent Ductus Arteriosus Occlusion Device Oral Presentation #3 Group 6 David Brogan, Darci Phillips & Daniel Schultz Advisor: Dr. Thomas Doyle

3/10/2003 Patent Ductus Arteriosus (PDA)  Ductus arteriosus (DA) allows blood to bypass pulmonary and enter systemic  DA normally closes within hrs of delivery (if not deemed abnormal/patent)  PDA affects 1800 babies/year in USA alone  Many adverse effects  growth retardation, breathlessness or lack of appetite  Most common problem is congestive heart failure

3/10/2003 Current Treatments  Drug therapy (indomethacin)  Implantable devices (most common are coils)  Usually need 3-4 coils  Difficult to remove and reposition  Invasive surgery (ligate the PDA to inhibit blood flow)

3/10/2003 Project Goals  To design, develop and patent a PDA occlusion device that can…  Be delivered via a catheter  Conform to the shape of the PDA and cause occlusion  Can be repositioned easily  Be cost effective (<$200)  Provide an initial success rate of 100%  More patient friendly procedure

3/10/2003 Current Best Competitor  Amplatzer Duct Occluder  Most effective, has highest success rate of current devices  Drawback - Not pliable  PDA must conform to shape of ADO

3/10/2003 Effect of Occlusion Device

3/10/2003 Our Design

3/10/2003 Delivery Path of Device

3/10/2003 Foam Issues  We can make a polyurethane foam with methylene bisphenyl diisocyanate (MDI), polytetramethylene glycol (PTMEG), 1,4- butanediol and water.  Have ordered MDI and 1,4-butanediol, but have not found a vendor yet to supply the PTMEG.  Contacted DuPont but was unable to secure a sample due to company restrictions.

3/10/2003 Work Completed  Conducted extensive research on other treatment methods (to avoid short comings on our design)  Met with Dr. Doyle to discuss our progress and future goals  Have placed order for foam chemicals (will arrive by Wednesday)  Have ordered and received Nitinol memory wire in two different diameter thicknesses  Have secured an In-Vitro PDA Simulation device for testing

3/10/2003 Foam Molds

3/10/2003 Current Status  Making final design refinements to device  Developing life-size PDA device prototype  Developing equations to model PDA testing apparatus  Making arrangements with Mechanical Engineering professor to have Nitinol wire machined here at Vanderbilt  Completing Design Safe and Innovation Work Bench assignments  Making necessary modifications to website

3/10/2003 In-Vitro Modeling Specs.  Pressure Drop : 100 mm Hg  Calculate flow inside PA using Hagen- Poiseuille Eqn.  Q = -ΔP *  *r 4 /(8*μ*L)  All variables are known, thus Q can be calculated easily

3/10/2003 Needs  Obtain missing foam ingredient (PTMEG)  Make arrangements to machine Nitinol wire  Meet with Dr. Doyle to discuss further progress

3/10/2003 Future Direction  Build scaled prototype with correct biomaterials  Figure out best way to secure Nitinol within device  Begin conducting pressure and durability tests in PDA simulated environment  Refine design based on testing  Talk with Dr. Doyle/Office of Technology Transfer about patenting this PDA Occlusion Device

3/10/2003 Contact Information  David Brogan    Darci Phillips    Daniel Schultz  